Last updated: 2026-10-14 20:26:40. Prices reflect the latest after-hours trading data. Stock price data is sourced from Massive.
PROCEPT BioRobotics Corporation (PRCT) operates in the SURGICAL & MEDICAL INSTRUMENTS & APPARATUS sector and is listed on NASDAQ. The stock is currently priced at $17.52, with a market capitalization of $1.12B and a P/E ratio of --. Over the past 52 weeks, its price has ranged from $16.67 to $38.11. This page covers its latest market performance, valuation, price trends and company information.
$1.12B | |
$19.00 | |
$103.81 | |
$15.38 | |
$19.10 | |
1.28M | |
1.43M | |
-- | |
$38.11 | |
$16.67 | |
-- | |
-- |
PROCEPT BioRobotics Corporation (PRCT) is trading at $17.63 in after-hours trading as of 2026-10-14 19:59:47, down 7.72% ($1.48) from the regular-session close of $19.10.
After-hours trading shows how investors are pricing PRCT after the regular session closes. The current after-hours price is below the regular-session close, indicating cautious after-hours sentiment.
Over the past seven days, PROCEPT BioRobotics Corporation (PRCT) moved from $17.82 to $17.52, representing a decline of 1.68% ($0.30).
The stock traded between $17.13 and $19.87 during the period. The latest price is near the lower end of the 7-day range, indicating moderate downward.
The average daily volume was 1.32 million shares, down versus the previous seven-day period, indicating lower trading activity.
Position in Range: 4.0%
PRCT is currently trading at $17.52, placing it 4.0% of the way from its 52-week low of $16.67 to its 52-week high of $38.11. This percentage reflects the stock's relative position within its 52-week trading range, not its valuation or future performance.
PROCEPT BioRobotics Corp is a surgical robotics company focused on advancing patient care by developing transformative solutions in urology. The company develops, manufactures, and sells the AquaBeam Robotic System and HYDROS Robotic System, image-guided, surgical robotic systems for use in minimally invasive urologic surgery, with an initial focus on treating benign prostatic hyperplasia, or BPH. Geographically, the company generates a majority of its revenue from the United States and also has a presence in markets outside the U.S.
| Industry | SURGICAL & MEDICAL INSTRUMENTS & APPARATUS |
| Employees | 888 |
| Exchange | NASDAQ |
| Company Website |
Eligible investors can buy real shares of PROCEPT BioRobotics Corporation (PRCT) through MEXC RealStocks. Follow these three steps to open a RealStocks account, transfer USDT, and place a US stock order.